Evidence map›Paper›PMID 28547387›Full record

ArticleBreast cancer (Tokyo, Japan)2018

Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan.

Yuri Mizota, Yasuo Ohashi, Takuji Iwase, Hiroji Iwata, Masataka Sawaki, Takayuki Kinoshita, Naruto Taira, Hirofumi Mukai, Seiichiro Yamamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuri MizotaDivision of Health Sociology, Center for Public Health Sciences, National Cancer Center, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan. ymizota@ncc.go.jp.
Yasuo OhashiIntegrated Science and Engineering for Sustainable Society, Chuo University, 1-13-27 Kasuga, Bunkyo, Tokyo, 112-8511, Japan.
Takuji IwaseBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation For Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Takayuki KinoshitaDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan.
Naruto TairaDepartment of Breast and Endocrine Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, Japan.
Hirofumi MukaiDepartment of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Seiichiro YamamotoDivision of Health Sociology, Center for Public Health Sciences, National Cancer Center, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan.

Funding

Minisry of Health, Labour, and Welfare H19-ganrinsho-ippan-006Ministry of Health, Labour, and Welfare H22-ganrinsho-ippan-035Ministry of Health, Labour, and Welfare H26-ganseisaku-ippan-001National Cancer Center 25-A-16National Cancer Center 26-A-20
6 · The paper itself

Abstract

backgroundAlthough there are a large number of epidemiological studies investigating the etiological role of lifestyle factors in breast cancer, there are few studies on the association between lifestyle factors and breast cancer prognosis. To investigate the influence of lifestyle factors such as diet and physical activity, use of complementary and alternative medicine, and psychosocial factors on prognosis, we designed a large-scale cohort study of female breast cancer patients in Japan.

methodsThe planned sample size is 7200. The cohort is being conducted in collaboration with several clinical trials, a cancer registry, and daily practice. Information on clinical factors, treatment, and follow-up will be obtained from the clinical trials and participating hospitals. A self-administered questionnaire is given to subjects before, immediately after, or 1 to 5 years after surgery. Blood and tissue samples are also collected. The primary endpoint is disease-free survival. The secondary endpoints are overall survival and health-related quality of life. The follow-up period will be at least 5 years after the last participant is enrolled. Recruitment began in November 2007. CURRENT STATUS: As of April 2017, there are 5852 patients enrolled in the study along with 1430 biological samples and the study is still ongoing. The number of subjects enrolled in the study is already the largest in the world.

conclusionsThe ROK study will provide much important evidence for breast cancer survivorship.

Indexed as

Cancer SurvivorsComplementary TherapiesLife StyleQuality of LifeAdultAgedAged, 80 and overBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansJapanMiddle AgedPrognosisPsychologyBreast cancerLifestylePatient cohortPsychosocial factorSurvivorship

Identifiers

PMID28547387
PMCPMC5741795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.